SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
FIBROSARC did not meet its primary PFS endpoint in the final analysi
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
This partnership has led to a 10% boost in delivery speed
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Subscribe To Our Newsletter & Stay Updated